ℹ️ What are Myeloproliferative Neoplasms (MPNs)?

Myeloproliferative Neoplasms (MPNs) are a group of chronic blood cancers in which the bone marrow overproduces mature blood cells. The three classic BCR-ABL1-negative MPNs are Polycythemia Vera (PV — excess red cells), Essential Thrombocythemia (ET — excess platelets), and Myelofibrosis (MF — progressive bone marrow scarring). About 90% of MPNs are driven by mutations in one of three genes — JAK2, CALR, or MPL — all converging on constitutive JAK-STAT signaling. Treatment ranges from phlebotomy and aspirin in low-risk PV to JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) and stem cell transplant in myelofibrosis.

💊 Primary Treatment Approaches

MPN treatment is tailored to the specific subtype (PV, ET, or MF) and risk level — ranging from phlebotomy and aspirin to JAK inhibitors and stem cell transplant:

🔬 Understanding MPNs — Overproduction, Not Failure

Myeloproliferative Neoplasms are the opposite of MDS. While MDS features bone marrow that fails to produce mature cells, MPNs are characterized by overproduction of mature, functional blood cells. The bone marrow is too active, producing excess quantities of one or more blood cell lineages — red blood cells, platelets, or white blood cells — leading to thickened blood, clotting risks, and eventual marrow scarring.

🩸

Polycythemia Vera (PV)

Too many red blood cells
Thick blood → clotting risk
JAK2 V617F in >95%

🩹

Essential Thrombocythemia (ET)

Too many platelets
Clotting + paradoxical bleeding
JAK2, CALR, or MPL mutations

🦴

Myelofibrosis (MF)

Bone marrow scarring
Fibrosis replaces marrow → cytopenias
Most aggressive classic MPN

📝 Note: CML Is Also an MPN

Chronic Myeloid Leukemia was historically classified as an MPN but is now treated as a distinct entity because of its unique biology (BCR-ABL1) and specific treatment (TKIs). The "classic" BCR-ABL1-negative MPNs discussed here are PV, ET, and MF. These share overlapping features and can evolve from one into another over time.

🧬 The Three Driver Mutations

~90% of MPNs are driven by a mutation in one of three genes — all converging on the same pathway: constitutive activation of JAK-STAT signaling, which drives uncontrolled blood cell production. These mutations are mutually exclusive — a patient carries one or none.

MOST COMMON

JAK2 V617F (~60% of MPNs)

A single point mutation in the Janus Kinase 2 gene that removes the auto-inhibitory function of the pseudokinase domain. The result: JAK2 is always turned on, continuously sending growth signals regardless of cytokine input.

• Present in >95% of PV, ~55% of ET, ~65% of MF
• Discovered in 2005 — transformed MPN diagnosis
• Allele burden matters: homozygous JAK2 (two copies) is associated with PV phenotype and higher risk
• JAK2 exon 12 mutations: rare variants found in ~3% of PV patients without V617F

2ND MOST COMMON

CALR Mutations (~25% of MPNs)

Mutations in calreticulin — an endoplasmic reticulum chaperone protein. Mutant CALR binds to the MPL (thrombopoietin receptor) and activates JAK-STAT signaling constitutively:

• Found in ~25-30% of ET and ~25-30% of MF; not found in PV
• Type 1 (52-bp deletion): more common in MF, intermediate prognosis
• Type 2 (5-bp insertion): more common in ET, generally favorable prognosis
• CALR-mutated ET has the lowest thrombosis risk of all MPN genotypes

LEAST COMMON

MPL Mutations (~5% of MPNs)

Mutations in the thrombopoietin receptor (MPL) itself — most commonly W515L/K — that cause the receptor to signal without binding thrombopoietin. Found in ~3-5% of ET and ~5-8% of MF. Never found in PV. Associated with older age, lower hemoglobin, and higher platelet counts.

~10%

"Triple Negative" MPNs

About 10% of ET and 10% of MF patients lack all three driver mutations. These"triple negative" cases often have non-canonical JAK-STAT pathway mutations and carry the worst prognosis in myelofibrosis — associated with higher leukemic transformation risk and shorter survival.

🩸 Polycythemia Vera (PV) — Too Many Red Cells

PV is characterized by uncontrolled red blood cell production, leading to dangerously thick blood. It is the most common MPN, with a median age at diagnosis of ~60 years. The overproduction of red cells increases blood viscosity, causing the hallmark risk of thrombosis — the leading cause of morbidity and mortality.

⚠️ Symptoms & Presentation

• Headache, dizziness, visual disturbances — from hyperviscosity
• Aquagenic pruritus — intense itching after bathing, often the most distressing symptom; caused by mast cell activation
• Erythromelalgia — burning pain and redness in hands/feet
• Plethoric (ruddy) complexion
• Splenomegaly (~70%)
• Thrombosis — stroke, MI, DVT/PE, hepatic vein (Budd-Chiari), portal vein

💊 PV Treatment

• Phlebotomy — first-line for ALL PV patients; target hematocrit <45% (CYTO-PV trial showed this reduces cardiovascular events by 4×)
• Low-dose aspirin — all patients unless contraindicated; reduces thrombosis risk (ECLAP trial)
• Hydroxyurea — cytoreductive therapy for high-risk PV (age ≥60 or prior thrombosis)
• Interferon alfa / Ropeginterferon — preferred in younger patients; can reduce JAK2 allele burden and achieve molecular responses
• Ruxolitinib (Jakafi®) — for hydroxyurea-resistant/intolerant PV; controls hematocrit, reduces spleen, and alleviates symptoms

🔄 Disease Evolution

PV can evolve into post-PV myelofibrosis (~10-15% at 15 years), characterized by progressive bone marrow fibrosis, splenomegaly, and worsening cytopenias. Transformation to AML occurs in ~3-5% of patients at 15 years (higher with certain treatments like prolonged alkylating agent exposure).

🩹 Essential Thrombocythemia (ET) — Too Many Platelets

ET is characterized by sustained overproduction of platelets, often with counts exceeding 450,000/μL (normal: 150,000-400,000). Despite having the most indolent course of the classic MPNs, ET carries significant thrombotic risk and the paradox of both clotting and bleeding complications.

🧪 The Thrombosis-Bleeding Paradox

While moderate platelet elevations increase clotting risk, extremely high counts (>1,000,000-1,500,000/μL) can paradoxically cause bleedingthrough acquired von Willebrand syndrome — large vWF multimers are consumed by the excess platelets. This is why aspirin must be used cautiously at very high platelet counts.

💊 ET Treatment Strategy

• Low risk (age <60, no prior thrombosis): observation ± aspirin
• High risk: cytoreduction with hydroxyurea (first-line), anagrelide (second-line — selectively reduces platelet production), or interferon alfa
• CALR-mutated, young patients may be safely observed even without aspirin — they have the lowest thrombosis risk

📊 Risk Stratification (IPSET-thrombosis)

The revised IPSET-thrombosis model stratifies ET patients into 4 risk categories based on age, thrombosis history, JAK2 status, and cardiovascular risk factors: Very Low (CALR+, age <60, no thrombosis), Low (JAK2−, age <60), Intermediate (JAK2+, age <60), and High (age ≥60 or prior thrombosis). Only high-risk patients clearly benefit from cytoreduction.

🦴 Myelofibrosis (MF) — Bone Marrow Scarring

Myelofibrosis is the most aggressive classic MPN. It can arise de novo (primary MF) or evolve from prior PV or ET (post-PV MF or post-ET MF). The hallmark is progressive bone marrow fibrosis — scar tissue replaces normal marrow, forcing blood production to shift to the spleen and liver (extramedullary hematopoiesis), causing massive organ enlargement.

⚠️ Clinical Features

• Massive splenomegaly — often extending below the umbilicus; causes early satiety, abdominal pain, and portal hypertension
• Constitutional symptoms — debilitating fatigue, night sweats, bone pain, weight loss, and fevers (cytokine-driven)
• Anemia — progressive, often transfusion-dependent
• Leukoerythroblastic blood smear — teardrop-shaped red cells (dacrocytes) and circulating immature myeloid cells
• "Dry tap" on bone marrow aspiration — the fibrotic marrow cannot be aspirated

📊 Risk Stratification (DIPSS / MIPSS70+)

Multiple scoring systems guide treatment:

• DIPSS: age, symptoms, hemoglobin, WBC, blood blasts
• MIPSS70+ v2.0: adds cytogenetics + mutations (ASXL1, SRSF2, EZH2, IDH1/2, U2AF1)
• High-molecular-risk (HMR) mutations: ≥1 of ASXL1, SRSF2, EZH2, IDH1/2 — independently shortens survival
• Risk determines transplant candidacy — the only curative therapy

💊 MF Treatment Landscape

Ruxolitinib (Jakafi®)

First-line JAK1/2 inhibitor. Dramatically reduces splenomegaly (~35% volume reduction in COMFORT trials) and constitutional symptoms. Modestly improves survival. Does not eliminate the MF clone or reverse fibrosis.

Fedratinib (Inrebic®)

JAK2-selective inhibitor. Effective as second-line after ruxolitinib failure. Requires monitoring for Wernicke's encephalopathy risk (thiamine levels).

Pacritinib (Vonjo®)

JAK2/IRAK1 inhibitor uniquely suited for patients with severe thrombocytopenia (platelets <50,000) — where ruxolitinib cannot be safely dosed. The only JAK inhibitor approved without a platelet requirement.

Momelotinib (Ojjaara®)

JAK1/2 + ACVR1 inhibitor. Uniquely addresses anemia in MF by inhibiting hepcidin (via ACVR1), improving iron availability. Approved for MF with anemia.

🏥 Allogeneic Stem Cell Transplant

The only curative treatment for myelofibrosis. Reserved for intermediate-2 and high-risk patients who are transplant candidates (typically age <70, good organ function). Transplant-related mortality is ~15-25%, but long-term disease-free survival is 40-60%. Ruxolitinib is often used as a bridge to transplant to reduce spleen size and improve symptoms pre-transplant.

⚠️ Complications & Disease Transformation

MPNs are chronic diseases that carry risks of both vascular complications and transformation to more aggressive diseases over time.

🫀 Thrombosis — The Major Killer

Thrombosis is the leading cause of morbidity and mortality in PV and ET:

• Arterial: stroke, MI, peripheral arterial occlusion
• Venous: DVT/PE, splanchnic vein thrombosis (Budd-Chiari syndrome, portal vein thrombosis — nearly pathognomonic for MPNs in young patients)
• Microvascular: erythromelalgia, digital ischemia, ocular migraine
• JAK2 mutation activates platelets, increases neutrophil extracellular traps (NETs), and promotes endothelial dysfunction

🔄 Disease Evolution Pathways

From	To	Risk (15yr)
PV	Post-PV MF	~10-15%
PV	AML	~3-5%
ET	Post-ET MF	~5-10%
ET	AML	~1-3%
MF	AML (blast phase)	~10-20%

Blast-phase MPN (AML from prior MPN) has very poor outcomes with standard chemotherapy.

🔮 Emerging MPN Therapies

Active areas of MPN drug development include: pelabresib (BET inhibitor — reduces bone marrow fibrosis when combined with ruxolitinib), imetelstat(telomerase inhibitor showing disease-modifying potential in MF), navtemadlin(MDM2 inhibitor targeting TP53 pathway), and combinations of JAK inhibitors with BCL-2/BCL-xL inhibitors to target the MPN stem cell. The goal is moving beyond symptom control toward true disease modification and clone elimination.

📚 Authoritative MPN Resources

These trusted organizations provide comprehensive, up-to-date information about MPNs:

🛠️ Tools & Focused Research

Scientific Literature

Search thousands of PubMed articles curated for Myeloproliferative Neoplasms.

Clinical Trials

Explore actively recruiting clinical trials for this disease group.

View Clinical Trials

📰 Latest News

Live

Disease Information